Characterization of skin adverse events associated with cetuximab: real-world insights from the two global pharmacovigilance databases of FAERS and VigiAccess. [PDF]
Li C +8 more
europepmc +1 more source
Adverse event profile of fondaparinux sodium: a disproportionality analysis based on FAERS, JADER, and VigiAccess databases. [PDF]
Jin W, Pan J, Yu L, Zhu M.
europepmc +1 more source
Real-world study of adverse events associated with sodium zirconium cyclosilicate based on FDA adverse event reporting system and VigiAccess database. [PDF]
Jia X, Liu L, Wang P.
europepmc +1 more source
Real-world safety of ixekizumab: a disproportionality analysis using the FDA adverse event reporting system and the VigiAccess databases. [PDF]
Zhao K +7 more
europepmc +1 more source
Antiplatelet therapy and central nervous system hematomas: a cohort study using real-world data from the FAERS and VigiAccess databases. [PDF]
Wang L, Cai H, Zhao S.
europepmc +1 more source
Incidence, timing, and clinical significance of adverse immune events after gene replacement therapy: A systematic review and meta-analysis. [PDF]
Maurizi N +7 more
europepmc +1 more source
Hereditary Angioedema Prophylaxis Therapy: Berotralstat and Lanadelumab Safety Profile. [PDF]
Donadoni M +7 more
europepmc +1 more source
Integrated Evidence from VigiBase and Clinical Trials: A Comprehensive Pharmacovigilance Analysis of Seven Glucagon-Like Peptide 1 Receptor Agonists (GLP-1 RAs). [PDF]
Li J, Liang J, Zhang W, He J, Ye X.
europepmc +1 more source
Real-World Sodium Fluoride Safety Signals: Dual-Database Pharmacovigilance. [PDF]
Ning W +8 more
europepmc +1 more source
Exploring potential associations between GLP-1RAs and depressive disorders: a pharmacovigilance study based on FAERS and VigiBase data. [PDF]
Wang M +6 more
europepmc +1 more source

